IBS - Irritable Bowel Syndrome
Conditions
Keywords
antigliadin, gluten free diet, transit
Brief summary
Gluten-free diet has been shown to improve gut symptoms in patients with celiac disease and also in adult patients with diagnosis of Irritable Bowel Syndrome (Rome III criteria). Antibodies to native gliadin (AGA) have been suggested as a potential diagnostic marker of response to GFD. However, this has not been tested in a prospective study in IBS patients. Identification of predictors of a symptomatic response to GFD within the IBS population would improve the clinical management of these patients. The purpose of this study is to evaluate the effect of gluten-free diet on gastrointestinal symptoms and gut motility in patients with Irritable Bowel Syndrome stratified according to their antigliadin antibodies status. Additional purposes include investigating effects gluten free diet may have on other parameters: * Improvement of mood * Quality of life and general well-being * Changes in gut microbiota
Interventions
OTHERGluten free diet
Gluten-free diet- Instructions provided by a dietitian
Sponsors
McMaster University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Intervention model description
Intervention GFD in IBS and HV(controls)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
* Adult patients * IBS diagnosis (Rome III) * Willingness to participate
Exclusion criteria
* history of any organic disease including celiac disease * Immune deficiency * Major abdominal surgery * Use of immunosuppressants, glucocorticosteroids or opioids * Use of antibiotics in the last 3 months
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Improvement on gastrointestinal symptoms | 4 weeks | Decrease \>2 points IBS Birmingham score |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Normalization of gastrointestinal transit | 4 weeks | (SHAPE 25-50 radiopaque markers) |
| Improvement anxiety and/or depression | 4 weeks | Decrease \>2 points Hospital anxiety and depression (HAD) score |
| Improvement somatization | 4 weeks | Decrease somatization scores (PHQ15) |
| Improvement quality of life and well-being | 4 weeks | Decrease in the psychological general well-being (PGWB) score |
| Changes in gut microbiota | 4 weeks | changes in microbial composition |
Countries
Canada
Outcome results
None listed